CD13


Also found in: Medical.
AcronymDefinition
CD13Cluster of Differentiation 13 (glycoprotein)
References in periodicals archive ?
The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas.
However, for other parameters such as TLC, Hb, platelet count, PB blast %, LDH, CD33, CD13, CD117, CD61, myeloperoxidase, CD2, CD5, CD7, CD34, HLA-DR, and CD10, no significant correlations were found.
Flow cytometry results showed a spectrum (94% of WBCs) of increased forward and side scatter, including CD33 on 100% of cells, CD13 on 64%, and a dim HLA-DR expression.
a) Sample BSA CD13 CD14 CD15 CD45 CD33 CD34 HLA-DR 1 0 263 1 126 292 371 488 305 2 3 182 0 108 228 292 356 246 3 1 195 3 1 343 385 502 352 4 2 383 1 235 420 478 3 390 5 0 168 2 0 256 1 282 295 6 0 252 1 308 337 350 304 318 7 1 172 0 272 316 0 1 294 8 0 234 2 179 285 1 279 218 9 2 262 2 272 214 268 327 254 10 0 330 1 0 307 331 352 298 11 2 234 0 302 181 242 276 202 (a) Results are given as the number of leukocytes/spot.
Immunophenotypic studies of the bone marrow were positive for CD13, CD33, and human leukocyte antigen (HLA)-DR and were negative for CD14.
TVT-Dox has been shown to be capable of selective binding to the CD13 receptor on endothelial cells in tumor blood vessels and effectively delivering the cytotoxic agent doxorubicin to the tumor blood vessels and adjacent tumor cells.
Myeloid CD markers CD Marker Result CD11b 3+ CD13 (LeuM7 pos CD14 (LeuM3) neg CD15 (LeuM1) neg CD33 (LeuM9) pos CD34 (My10) 2+ CD45 (HLE) pos CD61 (gp3a) 1+ CD64 neg CD71 pos CD117 pos HLA-DR neg Table 3.
Table 2 Selected flow cytometry panels and their objectives Antibody panel Objective CD5, CD19 CD10 Detects chronic lymphocytic leukemia CD20 CD11c, CD22 Detects B-cells or hairy cells CD33, CD13, HLADr Resolves myeloid leukemia cells CD7, CD1, CD2 Defines mature and immature T-cells subsets CD38, CD56, CD45 Resolves plasma and myeloma cells CD5 CD14 CD19 Defines T and B cells and monocytes in cerebral spinal fluid CD16 CD13, HLADr Defines acute promyelomonocytic leukemia CD71, CD3, CD4 Activation of T-helper/inducer cell subset CD20, CD79, CD22 Evaluation of CD79 to resolve certain B-cell malignancies CD33, UIC2, CD34 Evaluate drug resistance or progenitor cells Source: Roswell Park Cancer Institute
Immunophenotypic analysis of the leukemic cells showed proliferation of CD13 (75%), CD33 (59%), CD34 (95%), CD117 (68%), and HLA DR (44%).
The flow cytometry did not detect any immature lymphoid or myeloid precursor with expression of TdT, CD34, CD13, or CD33 in the bone marrow specimen, excluding B-lymphoblastic leukemia/lymphoma.
Isoelectric focusing (IEF) [3] and immunoblotting with CD13 monoclonal antibodies showed that the serum aminopeptidase N activity of these individuals was predominantly derived from a CD13 isoform that displayed a lower pI (3.
CD12 & CD13 for 765/400 kV transmission lines in NR I associated with Inter-regional System Strengthening Scheme for WR and NR-Part-B.